FiercePharmaOriginal article
{"a":[{"_":"GSK prepares frontline FDA bid for Jideytro, its first lung cancer drug","$":{"href":"/pharma/gsk-prepares-frontline-fda-bid-jideytro-its-first-lung-cancer-drug","hreflang":"en"}}]}
NDA FilingJideytroPositive
AI Analysis
Summary
GSK is preparing to submit Jideytro, its first lung cancer drug, to the FDA for first-line approval, supported by an unprecedented complete response rate in clinical data.
Outcome Details
GSK advancing first-line FDA approval bid with unprecedented complete response rate
Importance:7/10
Sentiment:
0.70
lung cancerfirst-line therapyFDA approvaloncologycomplete response rate
Related Companies
Read the original article
Published by FiercePharma on September 12, 2026 5:12 PM